The heart in hypertrophic cardiomyopathy A technical illustration of a heart whose muscular wall is abnormally thickened, traced over a fine measurement lattice with an electrocardiogram trace along the baseline. THICKENED SEPTAL WALL NARROWED CHAMBER FIG.01 HCM ECG SINUS

Clinical-stage biopharmaceutical · Hypertrophic cardiomyopathy

A selective therapy for the overactive heart.

We advance one investigational cardiac myosin inhibitor for hypertrophic cardiomyopathy, with positive Phase 2 results in both forms of the disease.

Explore the science View the pipeline

EYEAM is a clinical-stage biopharmaceutical company built on a single conviction: that hypertrophic cardiomyopathy deserves a medicine aimed at its mechanism, not only at the symptoms it produces.

One disease. One mechanism-directed compound. Studied in depth across both forms of the condition, and carried toward the people who live with it.

Start with the disease

The programme, in brief

A focused answer to a widely felt disease.

Three questions shape everything we do: what the disease is, how our medicine works, and where it stands in development.

01

The disease

In hypertrophic cardiomyopathy the heart muscle grows abnormally thick, stiffening the chamber and forcing the heart to work harder to move less blood. It is among the most common of the inherited heart conditions, and for a long time it has been managed around its symptoms rather than its cause.

Understand HCM
02

Our science

Our lead candidate is a selective cardiac myosin inhibitor. It is designed to act on the motor protein that drives contraction, easing the excessive force at the root of thickened heart muscle while leaving the wider system as undisturbed as possible.

See the mechanism
03

The pipeline

We advance a single lead programme across both obstructive and non-obstructive HCM. Mid-stage results have been positive in each, and the compound is now moving through global, late-stage clinical development toward the people it is meant to reach.

View the pipeline
≈1 in 500
Estimated prevalence of HCM in the United States
2 forms
Obstructive and non-obstructive HCM, both addressed
Ph. 2
Positive results reported in both forms of the disease
1 focus
A single mechanism, pursued with full attention

Why one programme

We chose to concentrate, and we mean it.

Rather than spread a broad portfolio thin across many therapeutic areas, EYEAM advances a single lead programme directed at a defined cardiac disease and grounded in clinical data. That decision shapes how we hire, how we set priorities, and how deeply we can understand the biology we are working in.

Depth is the point. A company that studies one mechanism can ask sharper questions of it, notice more, and follow the answers further than a company dividing its attention across a dozen.

Focus is not a constraint. It is the strategy.

DisciplineOne mechanism, cardiac myosin inhibition, studied where it matters most.
IndicationA single, well characterised disease with a clear unmet need.
EvidenceDecisions grounded in clinical data, not in breadth for its own sake.
ReachGlobal, late-stage development pursued through external collaboration.

Get in touch

Let us tell you more.

Clinicians, investigators, investors, potential collaborators, and prospective colleagues are all welcome to reach out. We read every message.

Contact us See open work